Evrysdi denied as non-formulary by Cigna?

Cigna's specific coverage criteria for evrysdi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Evrysdi as Non-Formulary

A non-formulary denial means Evrysdi (risdiplam) is not included on Cigna's covered drug list for your specific plan, or it is placed on a tier that requires special approval. Because risdiplam is an oral SMA therapy with no direct oral equivalent, non-formulary denials for it frequently succeed on exception appeal when the record shows that no formulary alternative is clinically appropriate.

Formulary exclusions are not absolute. Every plan that provides prescription drug benefits must have an exceptions process.

## Why It Is Appealable

Under ACA §2719 and the mental health/substance-use parity rules extended to medical benefits, plans cannot arbitrarily exclude drugs without a clinical basis. ERISA §503 requires a full-and-fair review of any adverse benefit determination. A formulary exception allows coverage when a formulary alternative would be clinically inferior or contraindicated for the specific patient. The internal appeal window is generally 180 days from the denial notice; external review must be filed within four months of the final adverse internal decision. Expedited review is available when health urgency requires it.

## Appeal Process and Timeline

1. Formulary exception request — submit through Cigna's pharmacy benefit management (PBM) portal, simultaneously with or just before the formal appeal, citing clinical need and the absence of a suitable formulary alternative. 2. Internal appeal — if the exception is denied, file a formal appeal within 180 days. Include the prescriber's letter and all supporting documentation. 3. Cigna's decision timeline — 30 days for non-urgent pre-service; 72 hours for urgent/expedited. 4. External review — request within four months of the final adverse internal decision if the internal appeal fails. 5. State insurance department complaint — for state-regulated plans, a concurrent complaint can accelerate the timeline.

## Documentation to Gather

• Prescriber's formulary exception letter — explaining why no covered formulary drug treats the patient's specific SMA type and clinical presentation adequately, and why risdiplam's oral formulation is medically necessary (relevant, for example, for patients unable to tolerate intrathecal administration).
• SMA diagnosis and type documentation — genetic results, neurology evaluation, and SMA type classification.
• Clinical rationale for oral route — if Spinraza (intrathecal) is the formulary alternative, document any clinical, anatomical, or access-related reason it is not appropriate for this patient.
• Functional status assessment — current standardized motor function evaluation with date, showing the urgency and clinical need.
• Prescriber attestation — statement that use of risdiplam aligns with the applicable neuromuscular society guidelines and the FDA-approved prescribing label.

## Criteria-Mapping Structure

Retrieve Cigna's formulary exception criteria from your plan's Evidence of Coverage and from Cigna's pharmacy clinical policy. Map each criterion to a specific chart finding or prescriber statement. Pay particular attention to the "clinically appropriate alternative" standard — if Cigna argues that a formulary drug exists, your appeal must directly address why that alternative is inadequate or inaccessible for this individual patient. A well-mapped exception request dramatically improves the probability of approval at the internal level before external review is even needed.